Phase 1 Rheumatoid Arthritis Trial, Recruiting NCT06543667 Sponsor: Iran University of Medical Sciences Condition: Rheumatoid Arthritis
Back to Rheumatoid Arthritis

Phase 1 Rheumatoid Arthritis Trial, Recruiting

NCT06543667
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who experience burning, itching, or a sensation of something in their eye
  • People who have been assessed as having moderate or severe dry eye
  • People aged between 18 and 70 years

Who may not be able to join:

  • People who have had eye surgery in the past
  • People who have a condition that weakens the immune system
  • People who are pregnant or breastfeeding
  • People who have abnormalities affecting the eyelids
  • People who have used any eye drops in the past year, other than artificial tears or lubricating ointments
  • People who have taken medications in the last three months that are known to affect tear production or the tear film (confirm with trial site)
  • People who have worn contact lenses in the last three months

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +982155661188

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Iran University of Medical Sciences
Registry
ClinicalTrials.gov
Start date
1 August 2024
Est. completion
1 January 2026

Where this trial is recruiting

Iran

Primary endpoints

Change in Inflammatory and Pro-inflammatory cytokines changes; Change in Ocular Surface Disease Index (OSDI)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov